VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma

BACKGROUND: Vascular endothelial growth factor (VEGF) isoforms, particularly the diffusible VEGF-121, could play a major role in the response of recurrent glioblastoma (GB) to anti-angiogenetic treatment with bevacizumab. We hypothesized that circulating VEGF-121 may reduce the amount of bevacizumab...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:BMC Cancer
Egile Nagusiak: Martini, Maurizio, de Pascalis, Ivana, D’Alessandris, Quintino Giorgio, Fiorentino, Vincenzo, Pierconti, Francesco, Marei, Hany El-Sayed, Ricci-Vitiani, Lucia, Pallini, Roberto, Larocca, Luigi Maria
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2018
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5946426/
https://ncbi.nlm.nih.gov/pubmed/29747600
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4442-2
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak